Cardiff Oncology to Participate in the UBS Global Biopharma Conference

Cardiff Oncology (CRDF) management will present and participate in investor meetings at the UBS Global Biopharma Conference on November 16–17, 2026.

Rhea-AI Summary

Cardiff Oncology (CRDF) management will present and participate in investor meetings at the UBS Global Biopharma Conference on November 16–17, 2026. President and CEO Mani Mohindru will lead a fireside chat on November 16 at 2:40 PM GMT. A live webcast will be accessible through the company website’s Events section, with a replay available after the presentation.

Argus Nov 3 session 3 alerts

+2.23% close to close 0.5x rel. volume Open Argus

Details

News Market Reaction – CRDF

$68.76M Mkt Cap at Peak Alert

On Nov 3, the day this news came out, CRDF closed 2.23% above the previous close. Our momentum scanner recorded 3 alerts for this stock that day.

Data tracked by StockTitan Argus for the Nov 3 session.

Key Terms

plk1 inhibition, mcrc

2 terms

plk1 inhibition medical

"leveraging PLK1 inhibition to develop novel therapies"

PLK1 inhibition means blocking the activity of the enzyme Polo‑like kinase 1, a protein that helps cells divide. For investors, it signals a drug approach aimed at slowing or stopping fast‑growing tumors by disrupting the cell’s “division machinery,” but it also raises safety and trial‑success questions because the same process is important in healthy tissues; clinical results and side‑effect profiles drive the investment impact.

mcrc medical

"first-line treatment of RAS-mutated mCRC"

Metastatic colorectal cancer is colorectal cancer that has spread from the colon or rectum to other parts of the body, most often the liver or lungs. For investors, it matters because developing treatments, diagnostic tests, or supportive care for this advanced stage can drive large clinical trials, regulatory decisions, and revenue potential—similar to how a product for a widespread, late-stage problem could reshape demand and company value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the UBS Global Biopharma Conference on November 16-17, 2026.

Details of the presentation can be found below.

Format: Fireside Chat
Presenter: Mani Mohindru, PhD (President and CEO)
Date: November 16, 2026
Time: 2:40 PM GMT

Interested parties can register for and access the live webcast for the conference by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Cardiff’s lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated mCRC, addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single-agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

For more information, please visit https://www.cardiffoncology.com.

Investor Contact: 
Candice Masse 
Astr Partners 
candice.masse@astrpartners.com 

Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com